Becton Dickinson (BDX): Evaluating Valuation After European Launch of Surgiphor and Recent Strategic Moves

Simply Wall St.11-29

Becton Dickinson (BDX) unveiled its BD Surgiphor Surgical Wound Irrigation System across select European countries following CE approval for the product. This marks a notable addition to its infection...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2587475669?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694","is_english":true,"pubTime":"2025-11-29 07:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2587475669","market":"nz","top_or_hot":-1,"title":"Becton Dickinson (BDX): Evaluating Valuation After European Launch of Surgiphor and Recent Strategic Moves","media":"Simply Wall St.","content":"<div>\n<p>Becton Dickinson (BDX) unveiled its BD Surgiphor Surgical Wound Irrigation System across select European countries following CE approval for the product. This marks a notable addition to its infection...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-evaluating-valuation-after-european-lau\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Becton Dickinson (BDX): Evaluating Valuation After European Launch of Surgiphor and Recent Strategic Moves</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBecton Dickinson (BDX): Evaluating Valuation After European Launch of Surgiphor and Recent Strategic Moves\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-29 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-evaluating-valuation-after-european-lau><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Becton Dickinson (BDX) unveiled its BD Surgiphor Surgical Wound Irrigation System across select European countries following CE approval for the product. This marks a notable addition to its infection...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-evaluating-valuation-after-european-lau\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0985489474.SGD","symbol_name":"First Eagle Amundi International AHS-C SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-evaluating-valuation-after-european-lau","article_id":"2587475669","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-evaluating-valuation-after-european-lau","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2587475669","pubTimestamp":1764372612,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Becton Dickinson (BDX) unveiled its BD Surgiphor Surgical Wound Irrigation System across select European countries following CE approval for the product. This marks a notable addition to its infection control and surgical offerings.\nSee our latest analysis for Becton Dickinson.\nThe Surgiphor launch is not happening in isolation. BD has also been investing in growth drivers such as the recent acquisition of Edwards Lifesciences’ Critical Care group and a board refresh, signaling a focus on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","BK4082":"医疗保健设备","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4504":"桥水持仓","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","BDX":"碧迪医疗","BK4588":"碎股","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","BK7067":"生物科技","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","BDX.AU":"BCAL DIAGNOSTICS LTD","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC"},"translate_title":"Becton Dickinson(BDX)：评估Surgiphor在欧洲推出后的估值以及最近的战略举措","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1.5,"BDX.AU":1.5},"content_text":"Becton Dickinson (BDX) unveiled its BD Surgiphor Surgical Wound Irrigation System across select European countries following CE approval for the product. This marks a notable addition to its infection control and surgical offerings. See our latest analysis for Becton Dickinson. The Surgiphor launch is not happening in isolation. BD has also been investing in growth drivers such as the recent acquisition of Edwards Lifesciences’ Critical Care group and a board refresh, signaling a focus on innovation and strategic execution. While the share price has climbed nearly 7% in the past month, Becton Dickinson’s one-year total shareholder return of -11% reflects lingering volatility and tempered market optimism, even as momentum has built recently. If you’re interested in discovering what other healthcare innovators are up to right now, you can see the full list for free with our dedicated screener: See the full list for free. With recent innovations and strategic acquisitions strengthening BD’s position, the key question for investors now is whether the current valuation reflects the company’s longer-term growth prospects or if an attractive entry point still exists. AdvertisementMost Popular Narrative: 3.7% Undervalued Compared to Becton Dickinson’s last close of $194.02, the most widely followed narrative sees fair value at $201.49. This narrow gap sets the scene for a debate on whether recent innovation and business changes can unlock more upside in the share price.  The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio (more than 90% of revenue), enabling higher cash flow predictability and margin improvement. In addition, anticipated aggressive share buybacks directly support EPS growth.  Read the complete narrative. Curious how breaking apart the business could change everything? The most popular narrative features surprisingly ambitious assumptions around margins and future buybacks that drive its fair value. Discover which bold numbers might change your outlook. Result: Fair Value of $201.49 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, ongoing trade tensions and looming execution risks from the business separation could quickly upend analyst expectations. This may make forecasts less certain. Find out about the key risks to this Becton Dickinson narrative. Another View: Market Comparisons Suggest a Premium While some models suggest Becton Dickinson may be undervalued, its current price-to-earnings ratio of 33x is above the US Medical Equipment sector average of 28.9x, and just over the fair ratio of 32.4x. This premium indicates that investors see extra value or are taking on more risk. So, does the market know something others do not? See what the numbers say about this price — find out in our valuation breakdown. NYSE:BDX PE Ratio as at Nov 2025 Build Your Own Becton Dickinson Narrative If you see things differently or want to take a deeper dive into the numbers yourself, you can easily craft your own story in just a few minutes with our platform. Do it your way. A great starting point for your Becton Dickinson research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Looking for More Smart Opportunities? Don’t limit yourself to just one company when so many promising trends are shaping tomorrow’s market. Uncover unique investing angles, shake up your strategy, and stay ahead by tracking what’s making a difference today.  Capture cash-flow potential by checking out these 920 undervalued stocks based on cash flows which contains stocks trading for less than their intrinsic value. Tap into the future by exploring these 28 quantum computing stocks as it highlights rapid breakthroughs in quantum tech and computing power. Secure steady income with these 15 dividend stocks with yields > 3% that consistently deliver yields above 3% to strengthen your portfolio’s foundation.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Becton Dickinson might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2587475669","isCrawlerRequest":true}